Parental willingness to pay and preference for human papillomavirus vaccine for girls aged 9-14 in subsidy scenarios in Shanghai, China
- PMID: 38977424
- PMCID: PMC11232639
- DOI: 10.1080/21645515.2024.2372883
Parental willingness to pay and preference for human papillomavirus vaccine for girls aged 9-14 in subsidy scenarios in Shanghai, China
Abstract
Multiple studies have documented low human papillomavirus (HPV) vaccine uptake among Chinese girls. It remains crucial to determine the parental willingness to pay (WTP) HPV vaccine for girls. We conducted a cross-sectional study recruiting 3904 parents with girls aged 9-14 in Shanghai, China, employing an online questionnaire with a convenience sampling strategy. Parental WTP, both range of payment and estimated point value, were determined for themselves (or wives) and daughters. HPV vaccine uptake was 22.44% in mothers and 3.21% in daughters. Respondents favored WTP ≤ 1000 CNY/138 USD for themselves (or wives), whereas showed increasing WTP along with valency of HPV vaccine for daughters (2-valent: 68.62% ≤1000 CNY/138 USD; 4-valent: 56.27% 1001-2000 CNY/138-277 USD; 9-valent: 65.37% ≥2001 CNY/277 USD). Overall, respondents showed higher WTP for daughters (median 2000 CNY/277 USD; IQR 1000-3600 CNY/138-498 USD) than for themselves (2000 CNY/277 USD; 1000-3500 CNY/138-483 USD) or wives (2000 CNY/277 USD; 800-3000 CNY/110-414 USD) (each p < .05). Furthermore, parental WTP was higher for international vaccine and 9-valent vaccine (each p < 0.05). Between two assumed government subsidy scenarios, parental preference for 9-valent vaccine remained consistently high for daughters (approximately 24% in each scenario), whereas preference for themselves (or wives) was sensitive to payment change between the subsidy scenarios. Using a discrete choice experiment, we found domestic vaccine was commonly preferred; however, certain sociodemographic groups preferred multivalent HPV vaccines. In conclusion, the valency of HPV vaccine may influence parental decision-making for daughters, in addition to vaccine price. Our findings would facilitate tailoring the HPV immunization program in China.
Keywords: China; girl; human papillomavirus vaccine; preference; vaccine intent; willingness to pay.
Conflict of interest statement
YL received the grant from MSD China for research in modeling and health economics of HPV vaccination in adolescent girls, and also kinetics of immune response to COVID-19 infection after recovery.
Figures

Similar articles
-
Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9-14 in a metropolis area of China: Evidence for developing a vaccination strategy.Vaccine. 2024 Apr 2;42(9):2246-2253. doi: 10.1016/j.vaccine.2024.02.076. Epub 2024 Feb 29. Vaccine. 2024. PMID: 38423812
-
Willingness to pay for HPV vaccine among female health care workers in a Chinese nationwide survey.BMC Health Serv Res. 2022 Nov 5;22(1):1324. doi: 10.1186/s12913-022-08716-6. BMC Health Serv Res. 2022. PMID: 36335333 Free PMC article.
-
Determinants of parental demand of human papillomavirus vaccination for adolescent daughters in China: Contingent valuation survey.Int J Health Plann Manage. 2024 Sep;39(5):1456-1481. doi: 10.1002/hpm.3818. Epub 2024 Jul 16. Int J Health Plann Manage. 2024. PMID: 39014911
-
Global parental acceptance, attitudes, and knowledge regarding human papillomavirus vaccinations for their children: a systematic literature review and meta-analysis.BMC Womens Health. 2024 Sep 27;24(1):537. doi: 10.1186/s12905-024-03377-5. BMC Womens Health. 2024. PMID: 39334328 Free PMC article.
-
Overcoming Barriers to Human Papillomavirus Vaccination in Guangdong Province, China.Vaccines (Basel). 2025 Apr 29;13(5):482. doi: 10.3390/vaccines13050482. Vaccines (Basel). 2025. PMID: 40432094 Free PMC article. Review.
Cited by
-
Factors affecting caregivers' HPV vaccination decisions for adolescent girls: A secondary analysis of a Chinese RCT.PLoS One. 2025 Jun 17;20(6):e0324260. doi: 10.1371/journal.pone.0324260. eCollection 2025. PLoS One. 2025. PMID: 40526724 Free PMC article. Clinical Trial.
References
-
- Centers for Disease Control and Prevention. HPV Vaccine Safety . 2021. [accessed 2023 Oct 10]. https://www.cdc.gov/hpv/hcp/vaccine-safety-data.html;.
-
- Villa A, Patton LL, Giuliano AR, Estrich CG, Pahlke SC, O’Brien KK, Lipman RD, Araujo MWB. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: umbrella review of systematic reviews. J Am Dent Assoc. 2020. Apr. 151(4):245–54.e24. doi:10.1016/j.adaj.2019.10.010. - DOI - PubMed
-
- Pan X, Lv H, Chen F, Wang Y, Liang H, Shen L, Chen Y, Hu Y. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system. Hum Vaccines Immunother. 2021;17(10):3823–30. doi:10.1080/21645515.2021.1939621. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources